{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:16:10Z","timestamp":1787786170215,"version":"build-2784847793"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women\u2019s Hospital"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008021","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]},{"name":"US Food and Drug Adminstration"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vertex"},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jaad.2020.09.084","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T11:37:22Z","timestamp":1602070642000},"page":"300-311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score\u2013matched cohort study"],"prefix":"10.1016","volume":"84","author":[{"given":"Maria C.","family":"Schneeweiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoyoung C.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wyss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jaad.2020.09.084_bib1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaad.2020.09.084_bib2","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaad.2016.04.054","article-title":"Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)","volume":"75","author":"Simpson","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"10013","key":"10.1016\/j.jaad.2020.09.084_bib3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Thaci","year":"2016","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.jaad.2020.09.084_bib4","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"issue":"10086","key":"10.1016\/j.jaad.2020.09.084_bib5","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaad.2020.09.084_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/all.14080","article-title":"Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry","volume":"75","author":"Ariens","year":"2020","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.jaad.2020.09.084_bib7","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","article-title":"Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"154","author":"Treister","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.09.084_bib8","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/ICO.0000000000002262","article-title":"Dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"39","author":"Liberman","year":"2020","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.jaad.2020.09.084_bib9","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40123-019-0191-9","article-title":"Ocular surface diseases induced by dupilumab in severe atopic dermatitis","volume":"8","author":"Maudinet","year":"2019","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.jaad.2020.09.084_bib10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses","volume":"79","author":"Hernan","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"10.1016\/j.jaad.2020.09.084_bib11","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/pds.1926","article-title":"A basic study design for expedited safety signal evaluation based on electronic healthcare data","volume":"19","author":"Schneeweiss","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.jaad.2020.09.084_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pds.3334","article-title":"The incident user design in comparative effectiveness research","volume":"22","author":"Johnson","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaad.2020.09.084_bib13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2415-11-14","article-title":"Incidence of new coding for dry eye and ocular infection in open-angle glaucoma and ocular hypertension patients treated with prostaglandin analogs: retrospective analysis of three medical\/pharmacy claims databases","volume":"11","author":"Schwartz","year":"2011","journal-title":"BMC Ophthalmol"},{"issue":"9","key":"10.1016\/j.jaad.2020.09.084_bib14","first-page":"778","article-title":"Economic burden of atopic manifestations in patients with atopic dermatitis\u2014analysis of administrative claims","volume":"13","author":"Suh","year":"2007","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.jaad.2020.09.084_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2415-9-13","article-title":"Estimate of the direct and indirect annual cost of bacterial conjunctivitis in the United States","volume":"9","author":"Smith","year":"2009","journal-title":"BMC Ophthalmol"},{"issue":"6","key":"10.1016\/j.jaad.2020.09.084_bib16","doi-asserted-by":"crossref","first-page":"e015795","DOI":"10.1136\/bmjopen-2016-015795","article-title":"Risk of allergic conjunctivitis in patients with type 1 diabetes mellitus: a population-based retrospective cohort study","volume":"7","author":"Chen","year":"2017","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.jaad.2020.09.084_bib17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jclinepi.2006.07.011","article-title":"Veteran\u2019s affairs hospital discharge databases coded serious bacterial infections accurately","volume":"60","author":"Schneeweiss","year":"2007","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"10.1016\/j.jaad.2020.09.084_bib18","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/pds.4006","article-title":"Positive predictive values of selected hospital discharge diagnoses to identify infections responsible for hospitalization in the French national hospital database","volume":"25","author":"Sahli","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"10.1016\/j.jaad.2020.09.084_bib19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.annepidem.2014.05.011","article-title":"Positive predictive value of primary inpatient discharge diagnoses of infection among cancer patients in the Danish National Registry of Patients","volume":"24","author":"Holland-Bill","year":"2014","journal-title":"Ann Epidemiol"},{"issue":"12","key":"10.1016\/j.jaad.2020.09.084_bib20","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jaad.2020.09.084_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"issue":"Suppl 2","key":"10.1016\/j.jaad.2020.09.084_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/pds.3263","article-title":"One-to-many propensity score matching in cohort studies","volume":"21","author":"Rassen","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"10.1016\/j.jaad.2020.09.084_bib23","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/sim.6058","article-title":"Metrics for covariate balance in cohort studies of causal effects","volume":"33","author":"Franklin","year":"2014","journal-title":"Stat Med"},{"issue":"25","key":"10.1016\/j.jaad.2020.09.084_bib24","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.jaad.2020.09.084_bib25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/EDE.0000000000000595","article-title":"A propensity-score-based fine stratification approach for confounding adjustment when exposure is infrequent","volume":"28","author":"Desai","year":"2017","journal-title":"Epidemiology"},{"issue":"3","key":"10.1016\/j.jaad.2020.09.084_bib26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/cpt.329","article-title":"Transparency and reproducibility of observational cohort studies using large healthcare databases","volume":"99","author":"Wang","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jaad.2020.09.084_bib27","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/art.40084","article-title":"Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study","volume":"69","author":"Kim","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.jaad.2020.09.084_bib28","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.2337\/dc19-0069","article-title":"Using real-world data to predict findings of an ongoing phase IV cardiovascular outcome trial: cardiovascular safety of linagliptin versus glimepiride","volume":"42","author":"Patorno","year":"2019","journal-title":"Diabetes Care"},{"issue":"23","key":"10.1016\/j.jaad.2020.09.084_bib29","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence\u2014what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jaad.2020.09.084_bib30","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/sim.2053","article-title":"The use of the propensity score for estimating treatment effects: administrative versus clinical data","volume":"24","author":"Austin","year":"2005","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.jaad.2020.09.084_bib31","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"issue":"10 Suppl 2","key":"10.1016\/j.jaad.2020.09.084_bib32","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1097\/MLR.0b013e318070c08e","article-title":"Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results","volume":"45","author":"Schneeweiss","year":"2007","journal-title":"Med Care"},{"issue":"12","key":"10.1016\/j.jaad.2020.09.084_bib33","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/ncprheum0652","article-title":"Primer: administrative health databases in\u00a0observational studies of drug effects\u2014advantages and disadvantages","volume":"3","author":"Suissa","year":"2007","journal-title":"Nat Clin Pract Rheumatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220326852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220326852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:57:23Z","timestamp":1759273043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220326852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0190962220326852"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.09.084","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score\u2013matched cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.09.084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}